Wells Fargo & Company Raises Integra LifeSciences (NASDAQ:IART) Price Target to $18.00

Integra LifeSciences (NASDAQ:IART) had its target price lifted by analysts at Wells Fargo & Company from $15.00 to $18.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has an “equal weight” rating on the life sciences company’s stock. Wells Fargo & Company‘s target price points to a potential upside of 8.11% from the company’s previous close.

Several other equities analysts also recently issued reports on the stock. Wall Street Zen downgraded shares of Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 18th. Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 13th. Truist Financial boosted their price target on Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. Citigroup reaffirmed a “neutral” rating and set a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. Finally, UBS Group assumed coverage on shares of Integra LifeSciences in a report on Tuesday. They issued a “neutral” rating and a $19.00 price target for the company. One equities research analyst has rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Reduce” and an average price target of $18.86.

Integra LifeSciences Price Performance

IART stock opened at $16.65 on Thursday. Integra LifeSciences has a 12-month low of $8.70 and a 12-month high of $20.49. The company has a market cap of $1.29 billion, a price-to-earnings ratio of -184.98, a PEG ratio of 1.18 and a beta of 1.22. The firm has a 50 day moving average of $17.70 and a 200-day moving average of $13.47. The company has a current ratio of 3.60, a quick ratio of 1.95 and a debt-to-equity ratio of 1.75.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.08. The firm had revenue of $418.76 million during the quarter, compared to analysts’ expectations of $417.54 million. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, equities analysts expect that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new position in shares of Integra LifeSciences in the 4th quarter valued at about $4,722,000. Hsbc Holdings PLC bought a new stake in shares of Integra LifeSciences during the 4th quarter worth $879,000. Tejara Capital Ltd lifted its position in shares of Integra LifeSciences by 42.6% during the 4th quarter. Tejara Capital Ltd now owns 171,813 shares of the life sciences company’s stock worth $2,134,000 after purchasing an additional 51,300 shares during the last quarter. Systematic Financial Management LP lifted its holdings in shares of Integra LifeSciences by 4.5% during the fourth quarter. Systematic Financial Management LP now owns 1,108,599 shares of the life sciences company’s stock worth $13,769,000 after buying an additional 48,094 shares during the last quarter. Finally, Paradigm Capital Management Inc. NY lifted its stake in shares of Integra LifeSciences by 50.6% in the first quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company’s stock valued at $37,800,000 after buying an additional 1,347,700 shares during the period. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.